Tema Etfs LLC bought a new stake in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 89,239 shares of the company's stock, valued at approximately $503,000. Tema Etfs LLC owned about 0.11% of Verve Therapeutics at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. BVF Inc. IL grew its position in Verve Therapeutics by 962.2% during the fourth quarter. BVF Inc. IL now owns 6,904,050 shares of the company's stock worth $38,939,000 after buying an additional 6,254,050 shares during the period. Point72 Asset Management L.P. acquired a new stake in Verve Therapeutics in the fourth quarter valued at $7,863,000. Schonfeld Strategic Advisors LLC increased its position in shares of Verve Therapeutics by 57.4% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 3,789,379 shares of the company's stock valued at $21,372,000 after buying an additional 1,382,176 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Verve Therapeutics in the 4th quarter valued at approximately $1,643,000. Finally, Jacobs Levy Equity Management Inc. raised its stake in Verve Therapeutics by 18.5% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,848,071 shares of the company's stock valued at $10,423,000 after purchasing an additional 288,678 shares during the last quarter. 97.11% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of brokerages have recently commented on VERV. Royal Bank of Canada lowered their price objective on Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research report on Tuesday, March 4th. HC Wainwright boosted their target price on shares of Verve Therapeutics from $15.00 to $25.00 and gave the company a "buy" rating in a report on Monday, April 14th. Cantor Fitzgerald raised shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Tuesday, April 15th. Canaccord Genuity Group upped their price objective on Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a report on Tuesday, April 15th. Finally, Guggenheim boosted their price target on Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a research report on Tuesday, April 15th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $25.75.
View Our Latest Analysis on VERV
Verve Therapeutics Stock Performance
Shares of VERV stock traded down $0.07 during trading hours on Friday, reaching $4.32. The company had a trading volume of 534,003 shares, compared to its average volume of 1,854,844. The company has a market capitalization of $384.65 million, a P/E ratio of -1.75 and a beta of 1.82. Verve Therapeutics, Inc. has a twelve month low of $2.86 and a twelve month high of $9.31. The stock's fifty day simple moving average is $4.64 and its 200 day simple moving average is $5.82.
Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.36. The company had revenue of $32.98 million during the quarter, compared to the consensus estimate of $7.13 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. As a group, equities analysts expect that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.
Verve Therapeutics Profile
(
Free Report)
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
Further Reading
Before you consider Verve Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verve Therapeutics wasn't on the list.
While Verve Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
